Pediatric Liver Disorders

The goal of the Pediatric Special Interest Group is to promote liver-related issues that affect infants, children and adolescents. The Pediatric SIG supports AASLD missions through committee memberships, educational programming and networking with related academic societies.

Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID‐19 in patients with chronic liver disease

Lukas Hartl, Katharina Haslinger, Martin Angerer, Georg Semmler, Mathias Schneeweiss‐Gleixner, Mathias Jachs, Benedikt Simbrunner, David Josef Maria Bauer, Ernst Eigenbauer, Robert Strassl, Monika Breuer, Oliver Kimberger, Daniel Laxar, Katharina Lampichler, Emina Halilbasic, Albert Friedrich Stättermayer, Ahmed Ba‐Ssalamah, Mattias Mandorfer, Bernhard Scheiner, Thomas Reiberger, Michael Trauner – 20 May 2022

Use of preprocurement biopsy in donation after circulatory death liver transplantation

Alexandra C. Bolognese, David P. Foley, Carrie J. Sparks, Adam K. Schneider, Anthony M. D'Alessandro, Nikole A. Neidlinger – 20 May 2022 – We perform routine preprocurement image‐guided percutaneous liver biopsies on potential donation after circulatory death (DCD) liver donors. The purpose of this study was to examine the impact of preprocurement liver biopsy on the use of livers from DCD donors.

Setting up criteria for drug‐induced autoimmune‐like hepatitis through a systematic analysis of published reports

Einar S. Björnsson, Inmaculada Medina‐Caliz, Raul J. Andrade, M. Isabel Lucena – 20 May 2022 – Nitrofurantoin, minocycline, methyldopa and infliximab, have been found to induce autoimmune‐like hepatitis (DI‐AILH). Evidence for other drugs and herbal and dietary supplements (HDS) is unclear. The aims of the study were to establish criteria to define and review the published evidence of suspected DI‐AILH.

Organoids and regenerative hepatology

Nidhi Jalan‐Sakrikar, Teresa Brevini, Robert C. Huebert, Fotios Sampaziotis – 20 May 2022 – The burden of liver diseases is increasing worldwide, with liver transplantation remaining the only treatment option for end‐stage liver disease. Regenerative medicine holds great potential as a therapeutic alternative, aiming to repair or replace damaged liver tissue with healthy functional cells. The properties of the cells used are critical for the efficacy of this approach.

Mas‐related G protein‐coupled receptor type D antagonism improves portal hypertension in cirrhotic rats

Lakmie S. Gunarathne, Indu G. Rajapaksha, Stephen Casey, Tawar Qaradakhi, Anthony Zulli, Harinda Rajapaksha, Jonel Trebicka, Peter W. Angus, Chandana B. Herath – 19 May 2022 – Splanchnic vasodilatation contributes to the development and aggravation of portal hypertension (PHT). We previously demonstrated that in cirrhosis, angiotensin‐ mediates splanchnic vasodilatation through the Mas receptor (MasR).

Subscribe to